Ovarian CancerOvarian Cancer Patient Advocacy Organizations
There are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver.
Web Exclusives – December 4, 2019 Many excellent organizations provide resources and support to the ovarian cancer community. These organizations are patient-centric and are committed to breaking down barriers to care for patients and caregivers, and strive to guide patients through their entire cancer care journey, from newly diagnosed patients to survivors.
The following are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver.
Recommended For You
FDA Approvals, News & UpdatesOvarian CancerOn April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.
Ovarian CancerLate last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer.
Ovarian CancerAs a retired college professor, Dr. McElhiney uses her personal experience with ovarian cancer to advocate for other patients, urging faster development of new treatment options.
Last modified: December 9, 2019
